LONDON & AMSTERDAM--(BUSINESS WIRE)--Today, the third and final day of BIO-Europe Spring® 2012, Index Ventures announced the launch of a EUR 150 million life science investment fund with heavy backing from GlaxoSmithKline (GSK) and Johnson & Johnson (J&J). The news was announced at BIO-Europe Spring 2012 in a plenary session entitled “Big pharma and venture capital: Two chefs in the kitchen.” BIO-Europe Spring is one of the largest life science partnering events in the world with over 2,000 delegates who engage in more than 11,000 one-to-one partnering meetings.
